Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | The potential role of emavusertib in patients with MDS and AML

David Sallman • 20 Mar 2023
ISAL 2023
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Emavusertib Venetoclax

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the potential role of the IRAK4 inhibitor emavusertib in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and further highlights the possibility of combining this agent with venetoclax to improve its activity. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals